Gong Zhao-Ting, Xiong Yu-Yan, Ning Yu, Tang Rui-Jie, Xu Jun-Yan, Jiang Wen-Yang, Li Xiao-Song, Zhang Li-Li, Chen Cheng, Pan Qi, Hu Meng-Jin, Xu Jing, Yang Yue-Jin
State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100037, People's Republic of China.
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Int J Nanomedicine. 2024 Feb 29;19:2005-2024. doi: 10.2147/IJN.S441307. eCollection 2024.
Exosomes derived from bone marrow mesenchymal stem cells (MSC-exo) have been considered as a promising cell-free therapeutic strategy for ischemic heart disease. Cardioprotective drug pretreatment could be an effective approach to improve the efficacy of MSC-exo. Nicorandil has long been used in clinical practice for cardioprotection. This study aimed to investigate whether the effects of exosomes derived from nicorandil pretreated MSC (MSC-exo) could be enhanced in facilitating cardiac repair after acute myocardial infarction (AMI).
MSC-exo and MSC-exo were collected and injected into the border zone of infarcted hearts 30 minutes after coronary ligation in rats. Macrophage polarization was detected 3 days post-infarction, cardiac function as well as histological pathology were measured on the 28th day after AMI. Macrophages were separated from the bone marrow of rats for in vitro model. Exosomal miRNA sequencing was conducted to identify differentially expressed miRNAs between MSC-exo and MSC-exo. MiRNA mimics and inhibitors were transfected to MSCs or macrophages to explore the specific mechanism.
Compared to MSC-exo, MSC-exo showed superior therapeutic effects on cardiac functional and structural recovery after AMI and markedly elevated the ratio of CD68 CD206/ CD68cells in infarcted hearts 3 days post-infarction. The notable ability of MSC-exo to promote macrophage M2 polarization was also confirmed in vitro. Exosomal miRNA sequencing and both in vivo and in vitro experiments identified and verified that miR-125a-5p was an effector of the roles of MSC-exo in vivo and in vitro. Furthermore, we found miR-125a-5p promoted macrophage M2 polarization by inhibiting TRAF6/IRF5 signaling pathway.
This study suggested that MSC-exo could markedly facilitate cardiac repair post-infarction by promoting macrophage M2 polarization by upregulating miR-125a-5p targeting TRAF6/IRF5 signaling pathway, which has great potential for clinical translation.
来源于骨髓间充质干细胞的外泌体(MSC-exo)被认为是缺血性心脏病一种很有前景的无细胞治疗策略。心脏保护药物预处理可能是提高MSC-exo疗效的有效方法。尼可地尔长期以来一直在临床实践中用于心脏保护。本研究旨在探讨尼可地尔预处理的间充质干细胞来源的外泌体(MSC-exo)在促进急性心肌梗死(AMI)后心脏修复方面的作用是否能得到增强。
收集MSC-exo和尼可地尔预处理的间充质干细胞来源的外泌体(MSC-exo),并在大鼠冠状动脉结扎后30分钟注射到梗死心脏的边缘区。在梗死后3天检测巨噬细胞极化,在AMI后第28天测量心脏功能以及组织病理学。从大鼠骨髓中分离巨噬细胞用于体外模型。进行外泌体miRNA测序以鉴定MSC-exo和尼可地尔预处理的间充质干细胞来源的外泌体(MSC-exo)之间差异表达的miRNA。将miRNA模拟物和抑制剂转染到间充质干细胞或巨噬细胞中以探索具体机制。
与MSC-exo相比,尼可地尔预处理的间充质干细胞来源的外泌体(MSC-exo)在AMI后对心脏功能和结构恢复显示出更好的治疗效果,并在梗死后3天显著提高梗死心脏中CD68⁺CD206⁺/CD68⁺细胞的比例。体外实验也证实了尼可地尔预处理的间充质干细胞来源的外泌体(MSC-exo)促进巨噬细胞M2极化的显著能力。外泌体miRNA测序以及体内和体外实验鉴定并验证了miR-125a-5p是尼可地尔预处理的间充质干细胞来源的外泌体(MSC-exo)在体内和体外发挥作用的效应分子。此外,我们发现miR-125a-5p通过抑制TRAF6/IRF5信号通路促进巨噬细胞M2极化。
本研究表明,尼可地尔预处理的间充质干细胞来源的外泌体(MSC-exo)可通过上调靶向TRAF6/IRF5信号通路的miR-125a-5p促进巨噬细胞M2极化,从而显著促进梗死后心脏修复,具有很大的临床转化潜力。